Luliconazole

Summary

Luliconazole (CHEMBL2105689) is an approved small molecule (ATC D01AC18); indicated across 3 conditions including tinea infection and tinea pedis.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: D01AC18
• Indications: 3 conditions
• Chemistry: 354.3 Da · C14H9Cl2N3S2

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL2105689
Name	Luliconazole
Type	Small molecule
Max phase	4
FDA approved	yes
PubChem CID	3003141
ATC	D01AC18
Molecular formula	C14H9Cl2N3S2
Molecular weight	354.3
InChIKey	YTAOBBFIOAEMLL-REQDGWNSSA-N

SMILES: C1[C@H](S/C(=C(\C#N)/N2C=CN=C2)/S1)C3=C(C=C(C=C3)Cl)Cl

IUPAC name: (2E)-2-[(4R)-4-(2,4-dichlorophenyl)-1,3-dithiolan-2-ylidene]-2-imidazol-1-ylacetonitrile

Also known as: Lulicon, Luliconazol, Luliconazole, Luzu, NND-502, PR-2699, LULICONAZOLE, SID144206495, SID144206527, SID144206804, luliconazole

Patent coverage: 474 distinct patent families (1,019 SureChEMBL compound mentions), from 2 matched compound structure(s). One matched structure accounts for 1,001 (98%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

3 indications (2 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
tinea infection	4	MONDO:0005982	EFO:0007510
tinea pedis	4	MONDO:0005984	EFO:0007512
tinea unguium	2	MONDO:0001628	MONDO:0001628

Clinical trials

Total trials: 0.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).